ARS Pharmaceuticals enters the post-Q1 period in a compressed vice: a quarterly earnings miss sent the stock down 6.5% on Friday to $7.43, while the lending market for its shares is as tight as it has been all year.
The week's defining event was the May 15 Q1 print. Revenue of $22.7M edged past the $22.2M estimate, but the EPS miss — $(0.61) against a $(0.52) consensus — landed hard on a stock already down 15% on the week and 9% over the prior month. That drop put SPRY near three-month lows, a stark contrast to mid-2025 when the stock was trading north of $15. The catalyst layered on top of an already combustible short structure.
Short interest is not a secondary consideration here — it is the central tension. At 65.2% of free float as of May 14, SPRY ranks among the most heavily shorted names on the market. That figure has been climbing steadily, up from roughly 58.4% at the start of April. The borrow market reflects that pressure fully: availability has tightened to zero — every share in the lending pool is currently lent out, matching the 52-week peak. The short score has been locked in the low-to-mid 85s all month, placing the stock in the first percentile of the broader universe by that measure. Cost to borrow, at 3.09%, is actually running below its early-April peak of around 5% — a notable divergence. Borrowing the stock has gotten cheaper even as the borrow pool has dried up entirely, which suggests the existing short base is well-established and not being aggressively added to on the margin. The put/call ratio told a sharply different story on Friday, however. It jumped to 0.30 — more than four standard deviations above its 20-day average of 0.13 — the biggest one-day defensive shift in the options market in months. That spike looks directly tied to the earnings release, with traders loading puts into and through the print.
The analyst community remains formally bullish but the gap between target prices and market reality has become hard to ignore. Coverage from Roth Capital (initiated September 2025 at Buy, $40 target), Cantor Fitzgerald (Overweight, $30), Leerink Partners (Outperform, $27) and Raymond James (Strong Buy, $28) collectively points to a mean price target of $26 — more than 250% above Friday's close. None of those actions are recent; the most recent analyst move on record is the Roth initiation from September 2025. That stale data means the Street's targets reflect a very different price context. What it does confirm is that no major firm has publicly walked away from the name — the bull case rests on the commercial trajectory of Neffy, the company's intranasal epinephrine product. Bears point to the deepening EPS miss and the cash burn, which the negative P/E and earnings yield figures underscore clearly.
Institutional ownership paints a picture of concentrated, specialist biotech money. RA Capital, OrbiMed, Deerfield, and Rubric Capital together control nearly a third of shares outstanding, with Millennium having added more than 5.1 million shares as recently as Q1 2026. Against that institutional anchor, Third Point increased its stake to one million shares on May 15 — a notable step from a generalist activist fund, even if the position remains modest relative to the specialist holders. The founder-heavy ownership structure, with the Lowenthal-Tanimoto Family Trust and individual founders holding combined stakes above 20%, also limits the float available to shorts — which is precisely why availability has hit zero.
Peer context adds pressure to the macro read. Close correlated names fared poorly on the week: TCRX fell 20.6% and HRTX dropped 29.8%, suggesting sector-wide headwinds compounded SPRY's stock-specific pain. NBIX and ARWR managed modest gains — the bifurcation points to earnings quality rather than pure tape risk driving the selloff.
The next scheduled event is a Q2 earnings call on June 24. Between now and then, watch whether the put/call ratio normalises — a reversion toward the 0.13 mean would suggest the options fear was purely event-driven — and whether the borrow pool shows any sign of loosening, which would be the first signal that short pressure is abating.
See the live data behind this article on ORTEX.
Open SPRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
